Discounted Cash Flow
Karyopharm Therapeutics Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $154.0k | $-109.6m | $-84.5m | -71153.9% | — |
| 2017 | $1.6m (942.2%) | $-129.0m (-17.7%) | $-73.8m (12.6%) | -8036.4% (88.7%) | — |
| 2018 | $30.3m (1790.1%) | $-178.4m (-38.3%) | $-161.5m (-118.9%) | -588.1% (92.7%) | — |
| 2019 | $40.9m (34.8%) | $-199.6m (-11.9%) | $-191.0m (-18.3%) | -488.1% (17.0%) | — |
| 2020 | $108.1m (164.3%) | $-196.3m (1.7%) | $-160.4m (16.0%) | -181.6% (62.8%) | $-2.72 |
| 2021 | $209.8m (94.1%) | $-124.1m (36.8%) | $-107.3m (33.1%) | -59.1% (67.4%) | $-1.65 (39.3%) |
| 2022 | $157.1m (-25.1%) | $-165.3m (-33.2%) | $-149.7m (-39.5%) | -105.2% (-77.9%) | $-2.02 (-22.4%) |
| 2023 | $146.0m (-7.0%) | $-143.1m (13.4%) | $-92.7m (38.0%) | -98.0% (6.9%) | $-1.25 (38.1%) |
| 2024 | $145.2m (-0.5%) | $-76.4m (46.6%) | $-127.6m (-37.6%) | -52.6% (46.3%) | $-0.63 (49.6%) |
| 2025 | $146.1m (0.6%) | $-196.0m (-156.5%) | $-75.4m (40.9%) | -134.2% (-155.1%) | $-17.93 (-2746.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.